PortalPublikationenImpact of Metastasectomy on Cancer Specific and Overall Surv...

Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry

Standard

Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. / Meagher, Margaret F; Mir, Maria C; Autorino, Riccardo; Minervini, Andrea; Kriegmair, Maximilian; Maurer, Tobias; Porpiglia, Francesco; Van Bruwaene, Siska; Linares, Estefania; Hevia, Vital; Musquera, Mireia; Roussel, Eduard; Pavan, Nicola; Antonelli, Alessandro; Zhang, Shudong; Ghali, Fady; Patel, Devin; Javier-Desloges, Juan; Bradshaw, Aaron; Rubio, Jose; Guruli, Georgi; Tracey, Andrew; Campi, Riccardo; Albersen, Maarten; Furlan, Maria; McKay, Rana R; Derweesh, Ithaar H.

in: CLIN GENITOURIN CANC, Jahrgang 20, Nr. 4, 08.2022, S. 326-333.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Meagher, MF, Mir, MC, Autorino, R, Minervini, A, Kriegmair, M, Maurer, T, Porpiglia, F, Van Bruwaene, S, Linares, E, Hevia, V, Musquera, M, Roussel, E, Pavan, N, Antonelli, A, Zhang, S, Ghali, F, Patel, D, Javier-Desloges, J, Bradshaw, A, Rubio, J, Guruli, G, Tracey, A, Campi, R, Albersen, M, Furlan, M, McKay, RR & Derweesh, IH 2022, 'Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry', CLIN GENITOURIN CANC, Jg. 20, Nr. 4, S. 326-333. https://doi.org/10.1016/j.clgc.2022.03.013

APA

Meagher, M. F., Mir, M. C., Autorino, R., Minervini, A., Kriegmair, M., Maurer, T., Porpiglia, F., Van Bruwaene, S., Linares, E., Hevia, V., Musquera, M., Roussel, E., Pavan, N., Antonelli, A., Zhang, S., Ghali, F., Patel, D., Javier-Desloges, J., Bradshaw, A., ... Derweesh, I. H. (2022). Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. CLIN GENITOURIN CANC, 20(4), 326-333. https://doi.org/10.1016/j.clgc.2022.03.013

Vancouver

Meagher MF, Mir MC, Autorino R, Minervini A, Kriegmair M, Maurer T et al. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. CLIN GENITOURIN CANC. 2022 Aug;20(4):326-333. https://doi.org/10.1016/j.clgc.2022.03.013

Bibtex

@article{b2ab7e48a7844bfb94030717a76fb840,
title = "Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry",
abstract = "BACKGROUND: Treatment paradigms for management of metastatic renal cell carcinoma (mRCC) are evolving. We examined impact of surgical metastasectomy on survival across in mRCC stratified by risk-group.METHODS: Multicenter retrospective analysis from the Registry of Metastatic RCC database. The cohort was subdivided utilizing Motzer criteria (favorable-, intermediate-, high-risk). Primary outcome was all-cause mortality (ACM)/overall survival (OS); secondary outcome was cancer-specific mortality (CSM)/cancer-specific survival (CSS). Impact of metastasectomy was analyzed via Cox-Regression analysis adjusting for potential prognostic variables and Kaplan-Meier analysis (KMA) within each risk-group.RESULTS: Four hundred thirty-one patients (59 favorable-risk, 274 intermediate-risk, 98 high-risk; median follow-up 27.2 months) were analyzed. Metastasectomy was performed in 22 (37%), 66 (24%), and 32 (16%) of favorable-, intermediate- and high-risk groups (P = .012). Median number of metastases at diagnosis differed significantly (favorable-risk 2, intermediate-risk 3.4, high-risk 5.1, P < .001). On Cox-regression, high-risk (HR = 1.72, P = .002) was associated with worsened ACM, while metastasectomy was associated with improved ACM (HR = 0.56, P = .005). On KMA, median OS (months) was longer with metastasectomy in favorable- (92.7 vs. 25.8, P = .003) and intermediate-risk (26.3 vs. 20.1, P = .038), but not high-risk (P = .911) groups. Metastasectomy was associated with longer CSS in favorable- (76.1 vs. 32.8, P = .004) but not intermediate- (P = .06) and high-risk (P = .595) groups.CONCLUSIONS: Metastasectomy was independently associated with improved ACM and CSM, as well as improved CSS and OS in favorable- and intermediate-risk mRCC patients. Metastasectomy may be considered as component of multimodal management strategy in favorable and intermediate-risk subgroups. In high-risk patients, metastasectomy should be deferred except in select circumstances.",
keywords = "Carcinoma, Renal Cell/pathology, Humans, Kidney Neoplasms/pathology, Metastasectomy, Prognosis, Registries, Retrospective Studies, Survival Rate",
author = "Meagher, {Margaret F} and Mir, {Maria C} and Riccardo Autorino and Andrea Minervini and Maximilian Kriegmair and Tobias Maurer and Francesco Porpiglia and {Van Bruwaene}, Siska and Estefania Linares and Vital Hevia and Mireia Musquera and Eduard Roussel and Nicola Pavan and Alessandro Antonelli and Shudong Zhang and Fady Ghali and Devin Patel and Juan Javier-Desloges and Aaron Bradshaw and Jose Rubio and Georgi Guruli and Andrew Tracey and Riccardo Campi and Maarten Albersen and Maria Furlan and McKay, {Rana R} and Derweesh, {Ithaar H}",
note = "Copyright {\textcopyright} 2022. Published by Elsevier Inc.",
year = "2022",
month = aug,
doi = "10.1016/j.clgc.2022.03.013",
language = "English",
volume = "20",
pages = "326--333",
journal = "CLIN GENITOURIN CANC",
issn = "1558-7673",
publisher = "Elsevier",
number = "4",

}

RIS

TY - JOUR

T1 - Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry

AU - Meagher, Margaret F

AU - Mir, Maria C

AU - Autorino, Riccardo

AU - Minervini, Andrea

AU - Kriegmair, Maximilian

AU - Maurer, Tobias

AU - Porpiglia, Francesco

AU - Van Bruwaene, Siska

AU - Linares, Estefania

AU - Hevia, Vital

AU - Musquera, Mireia

AU - Roussel, Eduard

AU - Pavan, Nicola

AU - Antonelli, Alessandro

AU - Zhang, Shudong

AU - Ghali, Fady

AU - Patel, Devin

AU - Javier-Desloges, Juan

AU - Bradshaw, Aaron

AU - Rubio, Jose

AU - Guruli, Georgi

AU - Tracey, Andrew

AU - Campi, Riccardo

AU - Albersen, Maarten

AU - Furlan, Maria

AU - McKay, Rana R

AU - Derweesh, Ithaar H

N1 - Copyright © 2022. Published by Elsevier Inc.

PY - 2022/8

Y1 - 2022/8

N2 - BACKGROUND: Treatment paradigms for management of metastatic renal cell carcinoma (mRCC) are evolving. We examined impact of surgical metastasectomy on survival across in mRCC stratified by risk-group.METHODS: Multicenter retrospective analysis from the Registry of Metastatic RCC database. The cohort was subdivided utilizing Motzer criteria (favorable-, intermediate-, high-risk). Primary outcome was all-cause mortality (ACM)/overall survival (OS); secondary outcome was cancer-specific mortality (CSM)/cancer-specific survival (CSS). Impact of metastasectomy was analyzed via Cox-Regression analysis adjusting for potential prognostic variables and Kaplan-Meier analysis (KMA) within each risk-group.RESULTS: Four hundred thirty-one patients (59 favorable-risk, 274 intermediate-risk, 98 high-risk; median follow-up 27.2 months) were analyzed. Metastasectomy was performed in 22 (37%), 66 (24%), and 32 (16%) of favorable-, intermediate- and high-risk groups (P = .012). Median number of metastases at diagnosis differed significantly (favorable-risk 2, intermediate-risk 3.4, high-risk 5.1, P < .001). On Cox-regression, high-risk (HR = 1.72, P = .002) was associated with worsened ACM, while metastasectomy was associated with improved ACM (HR = 0.56, P = .005). On KMA, median OS (months) was longer with metastasectomy in favorable- (92.7 vs. 25.8, P = .003) and intermediate-risk (26.3 vs. 20.1, P = .038), but not high-risk (P = .911) groups. Metastasectomy was associated with longer CSS in favorable- (76.1 vs. 32.8, P = .004) but not intermediate- (P = .06) and high-risk (P = .595) groups.CONCLUSIONS: Metastasectomy was independently associated with improved ACM and CSM, as well as improved CSS and OS in favorable- and intermediate-risk mRCC patients. Metastasectomy may be considered as component of multimodal management strategy in favorable and intermediate-risk subgroups. In high-risk patients, metastasectomy should be deferred except in select circumstances.

AB - BACKGROUND: Treatment paradigms for management of metastatic renal cell carcinoma (mRCC) are evolving. We examined impact of surgical metastasectomy on survival across in mRCC stratified by risk-group.METHODS: Multicenter retrospective analysis from the Registry of Metastatic RCC database. The cohort was subdivided utilizing Motzer criteria (favorable-, intermediate-, high-risk). Primary outcome was all-cause mortality (ACM)/overall survival (OS); secondary outcome was cancer-specific mortality (CSM)/cancer-specific survival (CSS). Impact of metastasectomy was analyzed via Cox-Regression analysis adjusting for potential prognostic variables and Kaplan-Meier analysis (KMA) within each risk-group.RESULTS: Four hundred thirty-one patients (59 favorable-risk, 274 intermediate-risk, 98 high-risk; median follow-up 27.2 months) were analyzed. Metastasectomy was performed in 22 (37%), 66 (24%), and 32 (16%) of favorable-, intermediate- and high-risk groups (P = .012). Median number of metastases at diagnosis differed significantly (favorable-risk 2, intermediate-risk 3.4, high-risk 5.1, P < .001). On Cox-regression, high-risk (HR = 1.72, P = .002) was associated with worsened ACM, while metastasectomy was associated with improved ACM (HR = 0.56, P = .005). On KMA, median OS (months) was longer with metastasectomy in favorable- (92.7 vs. 25.8, P = .003) and intermediate-risk (26.3 vs. 20.1, P = .038), but not high-risk (P = .911) groups. Metastasectomy was associated with longer CSS in favorable- (76.1 vs. 32.8, P = .004) but not intermediate- (P = .06) and high-risk (P = .595) groups.CONCLUSIONS: Metastasectomy was independently associated with improved ACM and CSM, as well as improved CSS and OS in favorable- and intermediate-risk mRCC patients. Metastasectomy may be considered as component of multimodal management strategy in favorable and intermediate-risk subgroups. In high-risk patients, metastasectomy should be deferred except in select circumstances.

KW - Carcinoma, Renal Cell/pathology

KW - Humans

KW - Kidney Neoplasms/pathology

KW - Metastasectomy

KW - Prognosis

KW - Registries

KW - Retrospective Studies

KW - Survival Rate

U2 - 10.1016/j.clgc.2022.03.013

DO - 10.1016/j.clgc.2022.03.013

M3 - SCORING: Journal article

C2 - 35585014

VL - 20

SP - 326

EP - 333

JO - CLIN GENITOURIN CANC

JF - CLIN GENITOURIN CANC

SN - 1558-7673

IS - 4

ER -